GRDN
GRDN
Guardian Pharmacy Services, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $377.43M ▲ | $58.37M ▲ | $9.82M ▲ | 2.6% ▼ | $0.16 ▲ | $23.61M ▲ |
| Q2-2025 | $344.33M ▲ | $55.57M ▲ | $9.03M ▼ | 2.62% ▼ | $0.15 | $18.25M ▼ |
| Q1-2025 | $329.31M ▼ | $51.34M ▲ | $9.45M ▼ | 2.87% ▼ | $0.15 ▼ | $18.54M ▼ |
| Q4-2024 | $338.57M ▲ | $50.35M ▼ | $11.94M ▲ | 3.53% ▲ | $0.2 ▲ | $21.8M ▲ |
| Q3-2024 | $314.39M | $165.49M | $-112.64M | -35.83% | $-2 | $-99.62M |
What's going well?
Revenue and profits are both rising at a healthy pace. The company is controlling costs well, leading to better operating margins. There are no one-time charges, so results reflect the true business performance.
What's concerning?
Profit margins are still low, and a high tax rate is limiting how much of the revenue turns into profit. Lack of detail on R&D and marketing spending makes it hard to judge long-term growth investments.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $36.49M ▲ | $390.04M ▲ | $194.54M ▲ | $183.76M ▲ |
| Q2-2025 | $18.82M ▲ | $356.33M ▲ | $176.66M ▲ | $169.56M ▲ |
| Q1-2025 | $14M ▲ | $334M ▲ | $170.78M ▼ | $156.09M ▲ |
| Q4-2024 | $4.66M ▼ | $320.81M ▼ | $170.83M ▼ | $142.67M ▲ |
| Q3-2024 | $37.22M | $348.03M | $214.13M | $127.57M |
What's financially strong about this company?
GRDN has nearly doubled its cash this quarter, paid down debt, and grown equity. The company is mostly funded by shareholders, not lenders, and has plenty of liquid assets to cover its bills.
What are the financial risks or weaknesses?
Payables and receivables are both rising, which could signal slower collections or delayed payments to suppliers. Goodwill and intangibles are a quarter of assets, so there's some risk if acquisitions don't perform.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.59M ▲ | $28.17M ▲ | $-8.97M ▲ | $-1.53M ▲ | $17.67M ▲ | $22.96M ▲ |
| Q2-2025 | $8.83M ▼ | $19.94M ▲ | $-13M ▼ | $-2.11M ▲ | $4.82M ▼ | $15.63M ▲ |
| Q1-2025 | $9.27M ▼ | $17.55M ▼ | $-5.54M ▲ | $-2.67M ▲ | $9.34M ▲ | $11.74M ▼ |
| Q4-2024 | $11.94M ▲ | $22.34M ▲ | $-6.62M ▲ | $-48.27M ▼ | $-32.56M ▼ | $17.84M ▲ |
| Q3-2024 | $-105.82M | $-2.16M | $-7.08M | $44.93M | $35.68M | $-7.29M |
What's strong about this company's cash flow?
Cash from operations and free cash flow both jumped this quarter. The company is self-funding, paying down debt, and building a healthy cash cushion.
What are the cash flow concerns?
A big part of this quarter’s cash boost came from delaying payments to suppliers, which may not be sustainable. Receivables and inventory are also rising, which could hurt future cash flow if not managed.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
Corporate Segment | $330.00M ▲ | $340.00M ▲ | $380.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.
GRDN combines strong revenue growth with a clearer, healthier balance sheet than in prior years, underpinned by consistent positive operating and free cash flow. Its niche focus on long‑term care, assisted living, and behavioral health, delivered through a hybrid local‑national model, creates close customer relationships and a service proposition that is harder to commoditize. A growing suite of technology tools further embeds the company in client workflows, enhancing retention and supporting its acquisition‑driven expansion strategy.
The most pressing concern is the dramatic deterioration in profitability, driven by a surge in operating expenses that turned a growing business into a loss‑making one. If elevated overhead levels persist, they could structurally compress returns, especially in a reimbursement‑constrained healthcare environment. Rising goodwill and intangible assets reflect acquisition risk and potential future impairments. The company also faces regulatory uncertainty, intense competition from larger and smaller rivals, and the challenge of aligning its innovation and growth ambitions with disciplined cost control and capital allocation.
The forward picture hinges on execution. If management can bring operating costs back in line with revenue and extract the expected benefits from its acquisitions and technology investments, the combination of strong top‑line growth, improved leverage, and solid cash generation could support a healthier long‑term financial profile. If, however, the recent cost structure proves sticky or competitive and regulatory pressures intensify, margins may remain under pressure despite rising sales and a stronger balance sheet. Monitoring the trajectory of operating expenses, margin recovery, and sustained free cash flow over the next few years will be key to understanding how GRDN’s story evolves.
About Guardian Pharmacy Services, Inc.
https://guardianpharmacy.comGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $377.43M ▲ | $58.37M ▲ | $9.82M ▲ | 2.6% ▼ | $0.16 ▲ | $23.61M ▲ |
| Q2-2025 | $344.33M ▲ | $55.57M ▲ | $9.03M ▼ | 2.62% ▼ | $0.15 | $18.25M ▼ |
| Q1-2025 | $329.31M ▼ | $51.34M ▲ | $9.45M ▼ | 2.87% ▼ | $0.15 ▼ | $18.54M ▼ |
| Q4-2024 | $338.57M ▲ | $50.35M ▼ | $11.94M ▲ | 3.53% ▲ | $0.2 ▲ | $21.8M ▲ |
| Q3-2024 | $314.39M | $165.49M | $-112.64M | -35.83% | $-2 | $-99.62M |
What's going well?
Revenue and profits are both rising at a healthy pace. The company is controlling costs well, leading to better operating margins. There are no one-time charges, so results reflect the true business performance.
What's concerning?
Profit margins are still low, and a high tax rate is limiting how much of the revenue turns into profit. Lack of detail on R&D and marketing spending makes it hard to judge long-term growth investments.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $36.49M ▲ | $390.04M ▲ | $194.54M ▲ | $183.76M ▲ |
| Q2-2025 | $18.82M ▲ | $356.33M ▲ | $176.66M ▲ | $169.56M ▲ |
| Q1-2025 | $14M ▲ | $334M ▲ | $170.78M ▼ | $156.09M ▲ |
| Q4-2024 | $4.66M ▼ | $320.81M ▼ | $170.83M ▼ | $142.67M ▲ |
| Q3-2024 | $37.22M | $348.03M | $214.13M | $127.57M |
What's financially strong about this company?
GRDN has nearly doubled its cash this quarter, paid down debt, and grown equity. The company is mostly funded by shareholders, not lenders, and has plenty of liquid assets to cover its bills.
What are the financial risks or weaknesses?
Payables and receivables are both rising, which could signal slower collections or delayed payments to suppliers. Goodwill and intangibles are a quarter of assets, so there's some risk if acquisitions don't perform.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.59M ▲ | $28.17M ▲ | $-8.97M ▲ | $-1.53M ▲ | $17.67M ▲ | $22.96M ▲ |
| Q2-2025 | $8.83M ▼ | $19.94M ▲ | $-13M ▼ | $-2.11M ▲ | $4.82M ▼ | $15.63M ▲ |
| Q1-2025 | $9.27M ▼ | $17.55M ▼ | $-5.54M ▲ | $-2.67M ▲ | $9.34M ▲ | $11.74M ▼ |
| Q4-2024 | $11.94M ▲ | $22.34M ▲ | $-6.62M ▲ | $-48.27M ▼ | $-32.56M ▼ | $17.84M ▲ |
| Q3-2024 | $-105.82M | $-2.16M | $-7.08M | $44.93M | $35.68M | $-7.29M |
What's strong about this company's cash flow?
Cash from operations and free cash flow both jumped this quarter. The company is self-funding, paying down debt, and building a healthy cash cushion.
What are the cash flow concerns?
A big part of this quarter’s cash boost came from delaying payments to suppliers, which may not be sustainable. Receivables and inventory are also rising, which could hurt future cash flow if not managed.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
Corporate Segment | $330.00M ▲ | $340.00M ▲ | $380.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.
GRDN combines strong revenue growth with a clearer, healthier balance sheet than in prior years, underpinned by consistent positive operating and free cash flow. Its niche focus on long‑term care, assisted living, and behavioral health, delivered through a hybrid local‑national model, creates close customer relationships and a service proposition that is harder to commoditize. A growing suite of technology tools further embeds the company in client workflows, enhancing retention and supporting its acquisition‑driven expansion strategy.
The most pressing concern is the dramatic deterioration in profitability, driven by a surge in operating expenses that turned a growing business into a loss‑making one. If elevated overhead levels persist, they could structurally compress returns, especially in a reimbursement‑constrained healthcare environment. Rising goodwill and intangible assets reflect acquisition risk and potential future impairments. The company also faces regulatory uncertainty, intense competition from larger and smaller rivals, and the challenge of aligning its innovation and growth ambitions with disciplined cost control and capital allocation.
The forward picture hinges on execution. If management can bring operating costs back in line with revenue and extract the expected benefits from its acquisitions and technology investments, the combination of strong top‑line growth, improved leverage, and solid cash generation could support a healthier long‑term financial profile. If, however, the recent cost structure proves sticky or competitive and regulatory pressures intensify, margins may remain under pressure despite rising sales and a stronger balance sheet. Monitoring the trajectory of operating expenses, margin recovery, and sustained free cash flow over the next few years will be key to understanding how GRDN’s story evolves.

CEO
Fred P. Burke
Compensation Summary
(Year 2024)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 92
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BROWN ADVISORY INC
Shares:1.76M
Value:$58.95M
BLACKROCK, INC.
Shares:1.74M
Value:$58.4M
VANGUARD GROUP INC
Shares:1.35M
Value:$45.35M
Summary
Showing Top 3 of 146

